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Sowa Rigpa institutions and practitioners have
growing interest in examining and legitimizing
Sowa Rigpa formulas vis-à-vis pharmacological
research methods, seeking scientific validation
of what they view as ‘potency’ and ‘purity’
for their formulas. Likewise, pharmacology
researchers have demonstrated renewed
interest in herbal medical traditions in mining
for new drugs to address resistance, toxicity,
and optimize what they view as ‘potency’ and
‘purity.’ However, differing conceptualizations
emerge when the pharmacological drug
discovery process is examined to determine
what is being analyzed, how it is doing so, and
what assumptions underlie such methods.
Whether a formula is ‘active,’ ‘toxic,’ or ‘effective’
hinges on assumptions, processes, and
methods that typically have low fidelity to
how Sowa Rigpa formulations function from
the Tibetan tradition’s perspective and are
actually administered to patients. This paper
argues that standard mainstream biochemical
pharmacology screening methods may not be

suitable for analyzing Sowa Rigpa formulas,
as they are traditionally compounded and
understood to function in concert with
multiple physiological pathways, rather than
one specific target. As such, we examine the
pharmaceutical research processes to identify
points of adherence and divergence with
conceptions of ‘potency’ and ‘purity’ in Tibetan
medical theory. We believe pharmacological
research institutions will be receptive to
traditional Sowa Rigpa menjor (sman sbyor), or
‘medicine compounding,’ theory due to benefits
it could provide biomedical drug discovery via
complementary understandings of compound
synergy and distinctly different concepts of
toxicity and purity. Accordingly, we suggest
that efficacy, activity, and safety of Tibetan
medicinal formulas will be more accurately
assessed by retaining fidelity to its own
conceptions of potency and purity.
Keywords: Sowa Rigpa, pharmacology, synergy, integrative
medicine, toxicology.

HIMALAYA Volume 39, Number 1 | 129

Introduction
Textually formalized in the twelfth century, Sowa Rigpa
(gso ba rig pa), or the ‘science of healing,’ is a scholarly
Asian medical system also known as Tibetan medicine.
It is still practiced as the dominant health care system
in many regions of the world, particularly in Tibet and
Tibetan-populated parts of China, Himalayan communities, areas of Tibetan refugee settlements in India, Nepal,
Bhutan, Mongolia, Buryatia, Russia, North America,
and Europe (Craig and Adams 2008; Yeshi et al. 2018).
The canonical root text called the Four Tantras (rgyud
bzhi), written in classical Tibetan, is still memorized by
students and used extensively by physicians,1 along with
hundreds of commentaries composed over centuries
that provide authority for theory and practice.2 Sowa
Rigpa shares extensive histories, texts and practices with
Indian Ayurveda, Chinese medicine, and Greco-Arabic
traditions, such as Unani. Various regions have developed
Sowa Rigpa traditions specific to their geographic and
socio-ecological context.3 Menjor (sman sbyor), or ‘medicine conjoining,’ is the medicine compounding theory
and practice within Sowa Rigpa.4 It is a subdiscipline of
dzéjor rikpa (rdzas sbyor rig pa), or the knowledge of how
substances combine, in which the subdiscipline addresses
making substances with therapeutic effect. Menjor provides
a corollary in our comparison with biomedical pharmacology, but with important and distinct concepts and
terms specific to each intellectual history and tradition.
In this paper, we acknowledge that one epistemology
can never fully map onto another. However, correlating
epistemologies and understanding basic structuring of
concepts is foundational for collaboration between two
intellectual traditions. This paper focuses on the Tibetan
tradition of Sowa Rigpa (bod lugs gso ba rig pa) and its menjor
specifically, but content may apply to other Sowa Rigpa
traditions as well.
Sowa Rigpa institutions and physicians have growing
interest in seeking compound evaluation by biomedical
pharmaceutical and clinical research methods (Reuter
et al. 2013; Luo et al. 2015) due to pressures to provide
evidence for efficacy and safety in national and international domains (Saxer 2013; Wangchuk & Tashi 2016).
Additionally, increased production of Sowa Rigpa formulas,
for both domestic and global markets, has required development of certain standards for production (Saxer 2012).
Yet, this widening industrial Sowa Rigpa pharmaceutical
assemblage (Kloos 2017) raises concerns within the Tibetan
medical field of proper formula efficacy as it threatens to
untether treatment and medicine production from physician care. National and international safety and efficacy
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evaluations of Sowa Rigpa formulas rely on biochemical
analytics in collaboration with pharmacology laboratories
in both academia and industry. Each collaborative side
often works from different meanings of ‘purity,’ ‘toxicity,’
and ‘efficacy.’ Standard biomedical analytic processes are
not designed to address distinct Tibetan medical conceptualizations of ‘potency,’ ‘activity,’ and multi-compound
synergy-by-design. In Sowa Rigpa research, few social
scientists and Sowa Rigpa physicians are familiar with
biomedical drug discovery and pharmaceutical research
processes. As such, they may mistakenly read results of
pharmacological analysis of Sowa Rigpa medicines as if
the analytic methods used actually assess activity and
toxicity of whole formulas as they behave in patient bodies
(see Schwabl and van der Valk 2019). Such limitations are
recognized by experienced scientists who analyze flaws in
published studies to design new ones (Brown et al. 2018).
Likewise, it is also important for Sowa Rigpa practitioners
to consider if the analytic methods applied are appropriate
for the formula being tested. National and international
restrictions on Tibetan formulations do not consider how
initial toxic ingredients may be chemically transformed
into therapeutic forms through Tibetan compounding
(Craig 2011a, 2011b, 2012), such as liquid mercury
converted to a mercury sulfide form thought non-toxic.
Improved research approaches to assess activity or
toxicity of compounds in the form actually administered
to patients may help remove obstacles for Sowa Rigpa
globally (Schrempf 2015). This article discusses limiting
assumptions of historical approaches and highlights
recent advances that contribute further rigor to future
collaborative endeavors.
Some biomedical researchers have growing interests in
collaborating with traditional medicine specialists toward
new drugs and combination therapies for unmet medical
needs (e.g., acquired drug-resistance and off-target
side-effects). This is evidenced by the Nobel prize awarded
for discovery of artemisinin (qinghaosu ‘青蒿素’ in Chinese)
to treat malaria (Shen 2015) and antimalarial Sowa Rigpa
drug leads (Wangchuk et al. 2012, 2013). However, many of
these studies are focused on discovery of new, patentable,
single agents and do not address formulas as they are
traditionally used. ‘Magic bullet’ monotherapy formulas
have been used extensively in biomedicine for the past
century (Strebhardt and Ullrich 2008), but they often
produce side-effects and select for resistance over time
(Zhang 2005). This approach has driven pharmaceutical
research on a constant search for new compounds to treat
the next drug-resistant disease agent. Decades of observing
how resistance emerges due to these modern monotherapy

treatments has shifted pharmacology to embrace the
concept of ‘combination therapy,’ where properly designed
positive combinations of two or more drugs can increase
efficacy (Butler 2019) and/or decrease toxicity for the
mixture relative to individual components (Jia et al. 2009).
Unfortunately, biomedical analysis of drug combinations
is complex and requires more elaborate and differentiated
testing than commonly done in most drug screening labs
(Foucquier and Guedj 2015). We propose that better understanding of principles behind standard medicinal formula
testing may enhance Sowa Rigpa practitioners’ ability
to assist pharmacological experiment design with direct
relevance to traditional medical practices.
Different types of collaboration analyzing traditional medicines have developed over the last decade. One type occurs
where a traditional medical institute provides single plant
materials or other multicompound formula parts for
chemical analysis. The samples undergo typical ‘natural
product’ screening operations, where the whole plant or
formula moves through staged chemical extraction to
separate potentially ‘active’ ingredient(s) before testing
in a specific disease model assay.5 A second collaboration
type seeks to evaluate an entire formulation to validate
and define specific biological activities affected, such
as recent network pharmacology studies of the Tibetan
medicine Drébu Sum Tang (’bras bu gsum thang), discussed
later.6 In a third type of collaboration a Tibetan medical
institute gives a pharmacology lab a medicinal substance,
or formulas containing the substance, to test for safety
and composition. An example here is tsotel (btso thal, lit.
‘refined ash’), an organometallic mercury sulfide complex
used in several important Tibetan medicines including
precious pills. Considered the pinnacle of Tibetan menjor
accomplishments, tsotel is often referred to as ‘purified’
mercury, a quintessential exemplification of the detoxification/potentiation approach through multicompound
formulas in Sowa Rigpa (see Gerke 2013a, 2013b, forthcoming). However, due to the known toxicity of the initial
ingredient, elemental mercury, it has raised concern
internationally and demands demonstration of its safety
mechanism through scientific investigation (Sallon et al.
2006, 2017; Liu et al. 2018).
In this paper, we present key paradigms underlying
both Tibetan menjor and pharmacology in their distinct
concepts of potency, toxicity, and activity due to multicompound synergistic effects. We discuss main Tibetan
menjor theoretical frameworks for synergy and detoxification that prioritize multicompound formulas over single
compounds. For pharmacology, we describe major historic
developments in drug discovery methods, highlighting

both strengths and limiting assumptions. We discuss
collaborative contexts within which pharmacological
analysis of Sowa Rigpa substances occur. We also describe
the basic drug discovery process often applied for Tibetan
formula analysis by introducing basic steps of modern
drug discovery highlighting noteworthy cases of antibiotic,
anticancer, and antiviral drug discovery. For complex
medicinal substances, such as Drébu Sum Tang and tsotel,
we present the limitations of standard chemical analytical
techniques and discuss recent advances.
A supplementary table summarizing comparative terms
and concepts of pharmacology and menjor discussed within
is available at (See Supplemental Table 1. Key Comparative
Concepts in Pharmacology and Tibetan Menjor (online
only)).
Distinct Concepts of ‘Purity’: Basic Units Begin the
Conversation
Pharmacologists employ the concept of ‘purity’ differently than the equivalent concept jangpa (sbyang pa) for
Tibetan menjor. In pharmacology, ‘purity’ derives from
the idea that a pure substance contains only one type
of atom or molecule (Pauli et al. 2014). In menjor, purity
is the degree to which a substance does no harm, often
requiring the combining and fusing of several complex
substances (rdzas) to achieve a ‘pure’ (dag pa) substance.
Pharmacological collaborations that engage concepts of
‘purity’ and ‘toxicity’ require a foundation of basic units
upon which chemists and Tibetan physician-pharmacists
can work together from their respective paradigms.
For example, the word ‘atom,’ often synonymous with
‘element,’ designates the smallest unit of a particular type
of physical matter. While derived from the Greek a tomos,
meaning ‘not cuttable,’ it is recognized in modern pharmacology that atomic matter is primarily energy—E=mc2
(Rainville et al. 2005). Accordingly, it is the energy form,
or orbital space of atoms that gives elements their specific
chemical properties—not a solid structure. Sowa Rigpa
menjor also developed out of early descriptions of matter
and energy. Early Buddhists in India described minute
units of matter with subtypes that corresponded to the
four basic elemental forms. Later, the concept developed
to that which is characterized in Tibet7 as dültren (rdul
phran), or momentary and infinitesimally small partless
particles. Dültren are understood to exhibit properties
dependent on context, rather than as inherent properties
of the particles themselves. Thus, the concept of ‘purity’
in menjor is not linked to a single-type particle and relates
closer to activities of the elemental dynamics.
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The elemental dynamics are five interactive properties
known in Tibetan as jungwa nga (’byung ba lnga), often
translated as ‘elements.’ Herein we use the term ‘dynamics’
to emphasize their understanding as properties exhibited
by matter and energy, not the physical substances. The
five dynamics are referred to simply as ‘earth,’ ‘water,’
‘fire,’ ‘wind,’ and ‘space,’ defined by their respective
properties of solidity/stability, cohesion/fluidity, maturation/heat, motility/movement, and interactive space.
For example, the physical substance of water has all five
dynamics of solidity, cohesion, heat, and motility. Materia
medica in Tibetan medicine, as with all matter including
our bodies, are classified and understood according to
properties of these dynamics.8 Here, we suggest that
‘elemental’ dynamic properties in Tibetan menjor provide
a working concept analogous to the pharmacological sense
of ‘chemical properties’. A chemical property is any property that becomes evident from observing a substance’s
dynamic behavior. Chemical properties are emergent,
just as in Tibetan menjor, elemental ‘dynamics’ describe
the emergent nature of interactions, the mode of reaction between substances, not the substances themselves.
Pharmacologists characterize atomic elements as behaving
in different ways depending on temperature, pressure,
context, and relation to other reactive substances. As such,
atomic elements could demonstrate behaviors of each of
the five dynamics depending on context. For example,
water molecules (containing elements of hydrogen and
oxygen) can demonstrate qualities of cohesion and solidity
in both solid and liquid forms—which are characteristics
of the water and earth dynamics, respectively. However, in
gaseous and superfluid forms where water demonstrates
no viscosity, water manifests the highly motile qualities of
the wind dynamic and the heat-producing kinetic energy
of the fire dynamic. In interaction with other substances,
water molecules may provide a structural substrate for
other molecule species to interact, in which its behavior
would demonstrate the space dynamic.

determining qualities and functional activities of materia
medica in Tibetan menjor known as ‘recognizing signs’ (ngos
’dzin rtags), or ‘markers’ of pathway activities, are similar
to techniques used for its patient diagnostics (Tidwell
2017). Thus, both biomedical and Sowa Rigpa intellectual
traditions have developed distinct systems of investigative
(analytic/direct perceptual) techniques for qualitatively
and quantitatively assessing and measuring the condition
of a patient or presence, amount, or functional activity of
a medicinal substance. A comparative analysis of different
assumptions and techniques pertinent to each tradition’s
assay approach is beyond the scope of this paper. However,
we suggest mutual recognition of each approach as a
bridge toward collaborative research aims.
In Sowa Rigpa, ‘taste’ is a cascade of activities that
commence with the initial interaction of a substance
with the tongue and related taste faculties in the mouth.
Neuroscientists are beginning to understand such a
concept as they assess how the sense of taste results from
specific chemical types interacting with spatial arrays of
particular sensing molecules, or ‘taste receptors’ (Adler et
al. 2000) in the mouth, nasal, and gut passages (Margolskee

Understanding Functional Activities in Sowa Rigpa
Menjor
Sowa Rigpa physician-pharmacologists have systematized
materia medica (see Figure 1) according to a substance’s
proclivity to manifest interactive properties of combinatorial dynamics in what they call ‘taste’ (ro), ‘potency’
(nus pa), ‘post-digestive taste’ (zhu rjes), and ‘quality’ (yon
tan). They assess how compounds interact physiologically
in both functional and dysfunctional pathways, defining
the nature of properties according to classes through
observations and techniques not unlike pharmacological
methods of an assay. The highly systematized techniques
132 | HIMALAYA Spring 2019

Figure 1. Classical Tibetan medical thangka scroll painting
reproduction based on Lhasa Men-Tsee-Khang set, initially
commissioned in 17th century and re-developed in the early 20th
century. The scroll painting depicts several geo- and woody/
herbaceous medicinals in Sowa Rigpa materia medica. Scroll paintings
created by Dharmapala Thangka Centre, School of Thangka Painting,
Kathmandu - Nepal <www.thangka.de>.

2015). Though seemingly simple, human ‘taste’ is actually
a very complex process of chemical identification for
survival of an organism (Shallenberger 1997; Margolskee
2015). In Sowa Rigpa, initial taste complexes facilitate
digestive processes in the gut that react with the ingested
substance to transform and transmit metabolites into
pathways and trajectories across organ systems, body
fluids, bodily constituents, and mental processes. Taste
describes the physiological activity that specific chemical
types initiate (Shallenberger 1997). ‘Post-digestive taste’
characterizes the activity that occurs once the substance
reacts in three gateway reactors in the gut that modify
the activity sequentially—‘decomposing béken,’ ‘digesting
tripa,’ and then ‘essence-waste separating heat-associated
rlung.’9 Post-digestive taste can be intentionally cultivated
in a substance through heating, drying, and processing
techniques that manipulate the elements. ‘Potency’ is
the final activity of the substance, resultant from its taste
profile reacting in the gut. These three characteristics—
taste, potency, and post-digestive taste—differentially
describe a substance’s overall activity by its body pathway
effects, delineated further according to ‘qualities’ that
determine activities on physiologic function and disease.

imbuing medicinally-potent components and qualities
(ibid: 691-700).Duk is defined as an entity difficult or
‘unsuitable’ (mi rung pa) to ‘metabolize’ (’ju ba), or to which
the body has metabolic ‘resistance’ (mi ’phrod pa, ma zhu ba).
The Four Tantras define ‘metabolize’ as proper separation
of nutritional essence and waste product, and their mobilization to respective bodily constituents and excrements.
Improper metabolism, vis-à-vis interference of duk, causes
bodily harm. Potencies are ‘smoothed’ (’jam btsal) and
formulas are developed through processes that heighten
certain qualities of a substance’s elemental dynamics,
creating greater potencies and directed effects. Certain
elemental dynamic combinations have ‘affinity’ (mthun pa)
that heighten their joint activity, whereas others adversely
relate by repelling, destroying, or eliminating activity.
‘Affinity’ and ‘adversity’ (mi mthun pa) relationships are
integrally considered in compounding formulations.
Expelling toxins and developing the desired therapeutic
effect is referred to as ‘purifying’ (sbyong pa; dag pa byed
pa). Taming and purifying involves adhering substances to
other components, substrates, catalysts, and transformative
fluids to make more stable compound forms.

Some substances function as predicted by their taste,
some by their post-digestive taste. Others contradict the
predicted effect from taste and/or post-digestive taste but
act according to their potency. Substance characteristics are
classified, enumerated, and explicated to provide the foundation upon which a formula is calculated and composed.
For example, a substance is primarily classified according to
its overall warming or cooling activities due to the dominant
dynamic combination driving its physiologic activity. It is
then elaborated according to its qualities classified by taste.10
Material Processing & Formula Compounding: Toxicity,
Purity, and Efficacy
The Four Tantras detail many minerals, gems, precious
substances, flora, and fauna used in the materia medica
which have toxins duk (dug) that are harmful to the body,
and at times lethal, if not properly detoxified—including
mercury (Yuthog Yönten Gönpo: 75-89; 626-630) (see
Figure 2, depicting Sowa Rigpa perspective on origin of
toxins (e.g., ibid 2008: 589-590)). Thus, Sowa Rigpa practitioners have developed extensive systems of transforming
substances to remove and transmute toxicity and optimize
therapeutic value—allowing medicinal qualities to emerge,
so to speak. This is referred to as düljong, ‘taming and purifying,’ in which medicinal substances are prepared through
distinct techniques to develop the medicinal qualities of
a substance, detoxify (dug ’don pa), ‘tame’ by eliminating
harmful components, and ‘purify’ it by retaining and

Figure 2. Classical Tibetan medical thangka depicting the origin of
compounded toxins as described in the Four Tantras and Blue Beryl
commentary, followed by examples of naturally occurring poisonous
flora, fauna and substances. Scroll paintings created by Dharmapala
Thangka Centre, School of Thangka Painting, Kathmandu - Nepal
<www.thangka.de>.
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Synergy is a term used in pharmacology to describe
an effect of two or more agents in combination that is
greater than their simple additive effect (Roell et al. 2017).
Since multiplying effects of combined dynamics, tastes,
post-digestive tastes, potencies, qualities, and other
processing contributions can heighten formula potency
(phan nus), the term synergy similarly characterizes
such interactions and processing methods. We call
the compounding approach based on this theory
‘synergy-by-design.’ Contemporary Tibetan medical
physicians use the term düljong as a Sowa Rigpa corollary
to the pharmacological processes of developing drugs
through compounding principles. This is because düljong
provides the classic Sowa Rigpa compounding framework
for ‘taming’ toxicities, ‘purifying’ multiplex compounds,
and developing medicinal effect.
In making any Tibetan medicine formula, a physician-pharmacist begins with a base medicinal compound
characterized by its taste, potency, and post-digestive
taste, as well as overall physiologic effect. Ideally, the
physician-pharmacist will have crafted the proper potency
profile of the substance through preliminary steps in
identification, harvesting and preparation before formulating it with other substances. Though single substances
contribute to Sowa Rigpa’s extensive drug library, monotherapies are considered susceptible to undesirable effects,
and thus formula design focuses on multicompound forms.
The following section outlines medicinal specimen preparation and formula development. The section is based on
the Four Tantras instructions for a medicinal flora class in
which the whole plant is used, called ngo men (sngo sman),
which we call ‘herbs’ here for short.11 Although specific to
this class, the process illuminates all medicinal substance
preparations prior to formulations.
Critical Steps of Medicine Compounding
Herbs are generally recognized as rough and cooling in
potency (ibid: 66; 697-698).They tend to have thick mucosal
constituents that tend to block rlung pathways, causing
fire-accompanying rlung in the digestive pathway to expel
heat externally and desiccate/deteriorate bodily constituents (ibid: 697).Thus, the potency of each herbal ingredient
must be prepared properly and ‘smoothed’ by combining
it with other compatible medicinal substances, or by
preparing it as a particular concentrated syrup decoction
(khaNDa) to avoid undesirable effects and focus medicinal
activities toward physiological targets (ibid: 698).
Preparing herbs follows a set of practices12 unique to Sowa
Rigpa, though vary regionally in implementation. The
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practices are methods to cultivate medicinal qualities in
harvested plants and when compounding formulas. They
begin with harvesting an herb in the proper environment, time, and conditions appropriate to maximizing
desired therapeutic qualities. One removes initial
‘toxicity,’ including mechanical removal of indigestible and metabolically-resistant parts, then dries and
stores the specimen according to its potency and qualities
(thereby potentiating the specimen).13 Subsequently,
one ‘smooths’ the specimen by balancing the potencies
vis-à-vis processing and formulation with other medicinal
substances. This is the key step that drives a multi-formulation approach described in the Four Tantras (ibid:
693, 697-700). The three methods for smoothing combine
substances to create a balanced formulation that: (1)
complements tastes profiles and potency characteristics to
address the overall hot-or-cold-nature of the condition to
be treated; (2) directs the formula toward a specific target
organ, fluid, or pathway imbalance; and (3) minimizes
deleterious effects of aggravating rlung, extinguishing the
digestive fire, and deteriorating bodily constituents. The
final step, called ‘compounding method for suitability’
(’phrod par sbyar ba), directs the overall formula toward
the appropriate taste, potency, or post-digestive taste
through further enhancement.
Other flora, fauna, mineral, and metal substances go
through similar processes of proper identification,
harvesting, detoxifying, smoothing, and compounding.
However, before detoxification, geologic materials often
undergo additional steps of specialized rinse-washing and
removal of undesired impurities and oxidation products.
Detoxifying often requires adding substances to expel
toxins, rigorously ‘smooth,’ cause caustic reactions, and
dry, heat, and cook. Furthermore, specific substances
are integrated along the way to direct therapeutic effect.
Intermediary steps also break down, open, and transform
substances through further conjoining. Geomedicinal
materials are often enclosed in specialized vessels and
adhered to substrates where they are cooked, burned,
incinerated, and otherwise modified.
Sowa Rigpa formulation also involves integration with
or adherence to a medicinal vehicle or substrate, menda
(sman rta), the medicine chariot or horse, which delivers
the proper activity to the patient. Mendas may variably be
part of ‘taming’ toxicities, smoothing function or directing
formula activity. Formula effectiveness is characterized
by the degree to which potency is properly imparted to
patient, as formula components are designed to affect
specific physiological pathways without toxicity effects,
digestive fire debilitation, or bodily constituent harm.

Throughout this process, detoxifying, smoothing, and
directing the formula’s potency are acts of ‘purification’
and ‘potentiation.’14 Processing creates different ‘efficiencies’ in delivering a formula’s potency that differ in speed
and resultant effect dependent upon degree and type
of processing. Textual indications provide the ideal, but
physician-pharmacists differentially employ steps dependent on their tradition and resources.
Tsotel quintessentially demonstrates the ability for Tibetan
medical physicians to tame, purify, and direct the potency
of a substance that is normally considered highly toxic.
Practitioners describe the process of detoxifying mercury
as ‘purification,’ whereby it is conjoined with sulfur,
and numerous herbs, metals, and mineral components
requiring many days of processing. The initial compounds
used to make tsotel include elemental (toxic) mercury
and various heavy metals. The very process of making
tsotel requires primarily ash forms of geologic and organic
substances and other materia medica ingredient additions,
in addition to compounding procedures to detoxify
and ‘smooth’ the final product. Because of its extensive
processing, tsotel is produced infrequently, rarely by individual physicians, and almost never in other Sowa Rigpa
traditions (Yeshi et al. 2018).
It is important to note that this processing is a chemical
transformation of mercury, so that it is no longer the
same substance. The processing is analogous to that used
in modern nanotechnology (Lee et al. 2013). Tsotel is used
to reduce toxicity and/or heighten potency of various
formulas including precious pills, by acting similar to a
menda or carrier. This also aligns with modern mechanistic
use of nanoparticles for drug delivery (Jong and Borm 2008).
By studying stages in making tsotel and the final product, a
wide spectrum of Sowa Rigpa formulas can be understood
since tsotel compounding epitomizes many menjor production principles (Troru Tsenam 2012).
Tibetan menjor has evolved with significant historical
developments. Yet, given the text’s position of authority
within the tradition, the contemporary framework has
largely retained fidelity to theory presented in the Four
Tantras15 despite regional differences in plants utilized,
therapies implemented, and illnesses recognized (Boesi
2006). Conversely, the developmental history of Western
pharmacology experienced some key turning points. We
detail those related to potency, purity, and synergy-by-design in the following section.
Fundamental Historical Developments in Pharmacology
Modern pharmacology has historical roots in an early
European medical context with characteristics that

resemble Sowa Rigpa. The work of Hippocrates (460-360
BC) contributed to a paradigm in which all disease originates from imbalance with nature. Rebalance is achieved
through herbal remedies, diet, exercise, and rest to restore
alignment of the four humors and relationship between
the person’s internal nature with the natural state of the
external environment. Much of the approach and materia
medica in the Hippocratic corpus, including both patient
care methods and medicinal properties of plants, continue
to strongly influence contemporary practitioners of biomedicine over 2000 years later (Hanson 2006).
However, in the late 1800s, German biologist and medicinal chemist Paul Ehrlich affected a paradigm shift in the
development of pharmacology. From the patient-focused
methods of Hippocrates, Ehrlich developed a concept to
design disease-specific chemical compounds he termed
‘magic bullets’ (magische Kugel) aimed toward microscopic
biological invaders (Strebhardt and Ullrich 2008). This
earned Ehrlich the name of father of modern chemotherapy and drug discovery methods (Bosch 2008). His
early research showed that chemical dyes could be used to
color specific cellular parts and types, and these new tools
allowed scientists to quantify the differences in biological response to different compounds based on changing
patterns of staining. He observed microscopic changes in
staining correlated with biological changes such as growth
and death of cells, and further related observed ‘activity’ to
specific chemical compositions.
Ehrlich’s use of staining led to the first systematic cellbased assays using dyes as ‘markers’ of biological change.
He promoted a theory that chemical substances with
special affinities for pathogenic organisms could be
designed to selectively eliminate such pathogens from
the body (Winau et al. 2004). ‘Affinity’ in the chemical
sense refers to the attractive force between substances or
particles causing them to enter into and remain in chemical combination. This concept also applies to chemical
substances having affinities to organisms. The magic bullet
was Ehrlich’s term for an ideal therapeutic agent that
killed only the organism targeted and was safe for the host.
He hypothesized specific structural orientations of chemical features of a compound could render it more toxic
to the pathogen than to host organism. In his 1908 Nobel
prize acceptance speech, he described the idea of how a
drug works based upon a specific chemical size, shape, and
charge that complements the biological target receptor—a
concept we now call ‘pharmacophore’ (Yang 2010), and
coined the term ‘chemotherapy’ (Ehrlich 1954).
Ehrlich’s most notable drug discovery was a chemical
transformation of arsenic (As) that reduced its toxicity in
animals and made it useful for treating syphilis. Ehrlich
HIMALAYA Volume 39, Number 1 | 135

developed the patented drug known as arsphenamine, or
Salvarsan (see Figure 3A), from the poisonous metal arsenic
by altering its chemical form and thus toxicity, an approach
conceptually similar to ‘taming toxicity’ in Tibetan menjor.
Salvarsan became the first patented, highly profitable,
global wonder-drug that solidified the single-drug
approach for most of that century. However, recent experiments using modern methods suggest the active material
is actually a mixture (Lloyd et al. 2005) (Figures 3B and C).
The single-drug approach uses a lock-and-key type model
to describe drug activity and specificity. Similar to a key,
a drug geometrically fits the appropriate active site (lock)
of an enzyme or other biological target (Figure 4A). Given
the correct key-like properties, the drug could then lock
or unlock a biological function in need of repair. An ideal
compound could uniquely destroy a pathogen with specific
drugs binding specific biological receptors of the pathogen
target. Using the concept of affinity, the ideal medicine—the
magic bullet—would have high affinity, vis-à-vis chemical
shape and property matching to the receptor. It would
also have high ‘efficacy,’ or a high degree to which it
performs the locking or unlocking. ‘Potency’ in drug
discovery is a measurement based on dose-response
curves in a given assay.
Ehrlich’s pharmacophore methods used cell and animalbased assays to systematically evaluate isolated chemicals.
These methods led to discovery of other patentable antibiotic and antiviral ‘wonder drugs’ that, along with related
public health measures, dramatically decreased deaths
from infectious diseases during the 20th century. Since
that time, biomedical research has primarily focused on

Figure 3. Salvarsan–the first ‘Magic Bullet.’ Chemical line and atomic
‘space filling’ models arsenic-As (purple) complexed with carbon (black),
oxygen-O (red), nitrogen-N (blue) and hydrogen-H (white). A) Theoretical
single structure containing two arsenic-As atoms original proposed by
Ehrlich. B) and C) Recent experiments find 2 cyclic forms with 3 and 5
arsenic-As (purple) dominated the active mixture. It is thought a further
oxidized form is actually responsible for the biological effect on the
pathogens in vivo, but none of form A) was observed.
(Salvarsan-montage. Wiki Commons, 2006: <https://commons.wikimedia.
org/wiki/File:Salvarsan-montage.png>)

Figure 4. A) ‘Lock and key’ pharmacophore models of drug activity. Drug compound (A) with complimentary shape and chemical properties can bind
selectively to a biological receptor and either move it toward action or inhibit an action due to physically blocking the site from active compound
binding. B) For a given molecule shape (conformation) individual atom properties can be clustered in 3D space and described numerically. C) 4-point
pharmacophore with chemical properties such as charge, hydrophilicity/lipophilicity, and donor/acceptor characteristics of individual atoms mapped
to 3D coordinates of cluster centers. This numerical abstraction allows researchers to use computers to predict activity of other chemicals related to
specific biological function.
(Nettles et al., 2007)
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identifying the single most active compound against a
specific disease or ‘pathogen’ when evaluating candidate
formulas, botanical specimens, or synthesized chemicals.
During the early discovery phase, ‘activity’ is measured as
degree of change in the marker used to quantify the assay,
irrespective of other systemic effects or overall benefit/
harm to patients. A highly ‘active’ drug may have toxicities
that pose potential harm to the general patient, but still
could be used for treatments requiring toxicities acting
on specifically located cell centers. An example of these
are cytotoxic compounds often used in cancer treatments.
Discoveries often come from serendipitous results as well
as strategic sampling of candidate compounds.
As with Ehrlich’s example, pharmaceutical research
initially focused on natural products to find active
compounds, such as arsenic, aspirin—the first patented
drug discovery from a botanical specimen. Paclitaxel
(marketed as Taxol®), is an important extract from the
Pacific yew tree discovered using general natural-product
screening methods during the 1960s that have now become
standard in the industry (Wani and Horowitz 2014).
How Pharmacologists Currently Analyze Natural Products
and Sowa Rigpa Formulas
As described in the introduction, three major collaboration
types occur in which pharmacologists analyze Sowa Rigpa
formulas: (1) single plant or multicompound formula for
active compound analysis; (2) complex compound analysis for multi-target/pathway analysis; and (3) complex
compound for composition and safety analysis. While (1)
and (3) still dominate research, (2) is a promising new field
as drug discovery interfaces biomedical informatics and
provides new insights by combining data derived from
older methods with new techniques. The next sections
detail some history, the analytical processes, and limitations for each type of collaboration.
I. Basic steps in active compound discovery & limitations
assessing Sowa Rigpa formulas
Early lock and key models helped pharmacologists standardize the drug discovery process. They developed
biological assays, or ‘bioassays,’ to test substances in
a controlled environment and standardize evaluation
processes. Bioassays are applied in vivo—in live animal or
plant, or in vitro—in tissue, cell, or isolated biological target
to determine the specific biological activity of a given
substance such as drug, compound, hormone, or enzyme.
As outlined in Table 1, the first step in drug discovery
has a biological focus: to determine a biological model
system that can quantifiably assay a specific compound

or formulation against a specific disease model. These
assays can fall into the general categories of phenotypic or
targeted approaches to drug screening. Phenotypic screens
are often performed in whole cell or whole organisms
while looking for measurable changes such as growth,
death, or other generally observable responses to drug
treatment.16 Targeted screens use specific cell types or
genetically identified proteins of interest that are over-expressed, isolated/purified, or otherwise engineered into
animals to test the specific hypothesis.
The second step has a chemical focus: to assemble a
‘library’ of potential new compounds or mixtures for
testing. This is applied to discover drugs from either
natural product or synthetic sources. Individual
compounds are first extracted and ‘purified’ by a range
of hydrophilic (water-loving) or lipophilic (fat-loving)
chemical solvents using physical separation methods
(Horowitz 1994; Wani and Horowitz 2014). Then single
molecules are characterized for elemental composition,
structure, and chemical properties, such as relative
affinity for aqueous or lipid phases. Using these properties,
libraries can be designed to either discover new leads in
a phenotypic assay or elucidate the ‘pharmacophore’ for
known active drugs through a ‘targeted’ screen. While a
number of keys may go into a lock, only those with chemical features placed in a complementary spatial array are
able to activate or deactivate a specific lock (Figure 4A).
With sophisticated computational informatics methods,
drug discovery programs are able to correlate these 3- and
4-dimensional chemical pharmacophore patterns with
specific activity to help further streamline the discovery/
optimization process (Figures 4B and 4C).
In developing a library of potential natural product
compounds to screen, many single compounds may be
Table 1. Basic Steps in Biomedical Drug Discovery

1. Define bioassay relevant to disease of interest
A. phenotype-based
B. target-based
2. Assemble chemical library for testing
3. Perform assay with library in triplicate
(include controls)
4. Evaluate results
5. Validate in different assays
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discarded during solvent-based extraction/separation
(Wani and Horowitz 2014). Different preparation and
extraction methods can result in differing composition
and concentrations of active (and undesired) ingredients.
Accordingly, to reduce experimental variability, standard procedures for drug screening analysis within a lab
are rarely changed unless a pharmacological rationale
has previously been determined (Heinrich et al. 2012).
However, modifying the preparation steps may be critical
to better test formulas as they are traditionally used. Thus
sample preparation/extraction provides an important
opportunity for Sowa Rigpa practitioners to affect study
design before data is collected.
The third step involves testing of the extractions in a
specific assay(s) with at least three separate runs to
determine deviations. Single compounds or extracted
mixtures identified as ‘active’ above a preselected threshold
are called ‘hits’ and validated with different or more
sensitive assays. Mixtures are typically further separated
into constituent molecular parts by chromatographic
fractioning. Each fraction is retested in the original assay
for changes in potency and further refined to determine
the most active ‘pure’ single compound in the fraction. If
the isolation procedure results in a total loss of activity,
complementary action can be suspected. This would ideally
direct the active complex into testing for synergy, but
rarely occurs due to complexity of those experiments. This
is another point where Sowa Rigpa practitioners may influence biomedical research in line with traditional teachings.
The fourth step is combining data and evaluating comparative activity/toxicity for compounds within the library
across all assays used for screening relative to the control
conditions. The best are selected as ‘lead’ drug candidates
and, from evaluation of chemical structure (relative to
activity), one develops a hypothesis for ‘why’ lead drugs
behave a specific way compared to similar compounds. A
better understanding of what was done in the previous
three steps allows the Sowa Rigpa practitioner to help
develop the testable hypotheses.
The last step is validating the leads and testing the pharmacology hypothesis in additional assays. This may include
different cellular activities or different models of fluid/
tissue environments the compound is expected to travel
during its physiological trajectory and metabolic lifecycle.
The value of a compound or mixture identified in this
five-step drug discovery process is typically measured by
how high a compound scores on its ability for debilitating
a pathogen or affecting the target activity verses how little
it harms the cellular infrastructure and/or function of the
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normal controls. The safety margin is the ratio of those
two potencies, known as the Therapeutic Index (TI). Those
with high TI are taken down the developmental path to
become drugs for humans. High toxic compounds (i.e., low
TI) may still be deemed valuable to destroy cancer cells.
Sowa Rigpa-specific examples of this screening approach
are Wangchuk and colleagues (2011, 2012).
Limiting assumptions of the screening approach
This screening model of biochemical pharmacology is
based on several assumptions and has related blind spots
if used alone. First, the approach assumes only specific
small compounds within a specimen or formula are
‘active,’ and thus necessary to replicate in the final drug
produced. If a compound undergoes this process and is
deemed ‘active’ or ‘inactive,’ ‘toxic,’ or ‘non-toxic,’ the
limitations and assumptions of the method are often
overlooked. Second, the model assumes bioassay environments can replicate cellular environments similar
to how the compound works in the human body and
may be extrapolated as such.17 Third, the model assumes
the manner in which a drug works is by either directly
debilitating a pathogen, or heightening immune or some
other innate responses that directly address a pathogen
or malfunctioning gene/protein. In vitro assays cannot
exactly replicate in vivo environments of a patient actually being orally, intravenously or anally administered
a formula, however the relative ease of analysis and a
century of short-term successes has fueled this system.18
While pharmaceutical research often ignores synergistic
activities beyond the single lock-and-key model, we
propose that incorporating menjor theory into design/
analysis of new screening studies and analysis of historical
data, as described above, has potential to increase relevance related to results seen in patients.
II. Complex compound analysis for multi-target/pathway
analysis via network pharmacology
While large-scale drug screening began as a somewhat
random way of relating chemistry and biology, modern
drug discovery analytics allow more rigorous understanding
of disease pathways based upon decades of previous
single-compound screening. In our second type of menjor/
pharmacology collaboration chemogenomic methods allow
one to rapidly relate chemical structures of many drug-like
molecules to complex cellular protein-receptor networks,
known as molecular signaling pathways. Pharmacophores
(illustrated in Figure 4B and 4C) can be used to predict
molecular targets (Nettles et al. 2006; Wang et al. 2016).

The relatively new science of network pharmacology linked
with systems biology and metabolomics shifts the single
drug, single target paradigm by looking at how specific
medicines show additive or synergistic effect by acting on
multiple targets, pathways, and micro-environments (Li
and Zhang 2008; Ji et al. 2009; Schwabl and van de Valk
2019; Yuan et al. 2017). Biological pathways and networks
are foundations of normal cell development, growth and
function. Abnormalities in signaling pathways can result
in cell function aberrations, and hence, disease. Modeling
abnormalities related to changes in specific genes allows
small molecule drugs and antibodies to be developed that
target key points along pathways with altered protein
translation that may lead to disease (Liao et al. 2016),
and whose proper rehabilitation can lead to normal cell
function. Such pathway recognition can provide strategic diagnostic and treatment tools, as well as analysis
of traditional formulas. Well-designed new studies can
begin to unveil various modes of synergistic effects and
develop testable models to account for such effects (Tang
et al. 2015). For example, integrating systems biology and
chemical informatics through this approach can allow
researchers to address limitations of single compound
analysis by using more integrative methods for
multicompound formulas.
A recent team, from China and Germany, used the network
pharmacology approach to study anti-tumor activities
from the Tibetan medicine Drébu Sum Tang (Zhao et al.
2018). They used established computational methods to
correlate ‘pharmacophores’ of single-compounds in the
multi-compound formula to specific protein targets (Wang
et al. 2016), then combined literature searching, computational simulations, and statistical clustering to predict/
select known gynecologic cancer targets for testing. A
dried, whole-formula methanol/water extract was tested
for anti-proliferation activities across the three selected
bioassays. This approach allowed them to experimentally
evaluate hypothetical target mechanisms, predicted by
the pharmacophore mapping, and propose linked activity
pathways for future studies. It also allowed testing the
whole formula extract including synergistic effects that
would not be present with single-compound isolates. Given
this type of foundational work, future studies can compare
specific single-compounds and combination results in a
single experimental design to investigate nuanced synergy
mechanisms of the whole formula.
It is important to realize that this network method still
depends upon—and is limited by—data derived from
single herb/ingredient screening methods described
previously. Fortunately, for Drébu Sum Tang, and herbal
formulas in general, abundant carbon-containing/organic

small-molecules can be readily extracted with standard
solvents, characterized, and assayed using pharmacology’s purity and potency standards. Accordingly, Zhao and
colleagues (2018) were able to use chemical activity data
from previous natural product screening across multiple
biological assays to design their study. Given chemical
structures of single small molecules extracted from the
individual herbs, pharmacophore tools can use historical
chemical screening data to predict biological targets and
aid selection of best assays to test whole formula activity.
This study highlights the emerging multidisciplinary techniques needed to understand complex biopharmacology
of multicompound formulas and the unique perspective
on the body, body pathways, and menjor activities used by
Sowa Rigpa. Sowa Rigpa formulas tested via in vivo and in
vitro models include, among others,19 testing the growth
inhibitory property of a formula called Yukyung Karné
in several cell lines to assess its anticancer properties
(Choedon et al. 2014).
In Sowa Rigpa, ‘purity’ is achieved through processing
or combining substances, and Drébu Sum Tang combines
three chemically complex herbal ingredients toward
a more Sowa Rigpa ‘pure’ and ‘potent’ medicine used
in humans. Biomedical experiments typically begin by
finding which pharmacologically ‘pure’ single compound
or element in a formula is the most quantifiably ‘potent’,
or active, in some number of specific screening assays.
But, since serendipitous discovery of synergy-based drug
cocktails for HIV in the early 90s (Barry and St. Clair 1996),
biomedical methods have evolved to better understand
chemical and biological mechanisms for such effects
(Diallo et al. 2003).
Now ‘drug cocktails’ combining multiple ‘pure’ compounds
with multiple ‘targets’ are standard and recognized for
minimizing resistance and maintaining potency for a range
of diseases through the power of synergistic combinations
(Jia et al. 2009). Although methods allowing for investigation of complementarity among pharmacologically ‘pure’
compounds are becoming more popular (Yuan et al. 2017),
the potential for understanding the therapeutic values of
synergistic-design in traditional multi-compound formulas
remains largely untapped.
III. Complex compound composition-safety analysis:
differing purity-toxicity concept relations
In our third type of Tibetan-menjor/pharmacology
collaboration, assumptions of toxicity shape the analytical techniques employed, and understanding different
concepts of ‘purity’ and ‘potency’ becomes critical. As
described earlier, ‘purity,’ in pharmacology, is the degree
to which a substance is made of only one type of element
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or compound, and ‘potency’ is any quantitative measure
of concentration-dependent activity. Therefore, from a
pharmacological perspective, a ‘potent’ toxin is a ‘pure’
substance where a small amount can cause great harm to
healthy animals or cells. In Sowa Rigpa, ‘purity’ is achieved
through processing or compounding substances to offset
potential harm and impart full potency or beneficial
effect of the combination to a specific patient. For our last
example, we contrast the study of Drébu Sum Tang introduced above (Zhao et al. 2018) with current pharmacology
research of mercury-containing tsotel.
Unlike Drébu Sum Tang, tsotel is not a mixture of small
organic molecules that can be easily separated, characterized, and tested. Likewise, distinct from both Drébu Sum
Tang and taxol, tsotel does not dissolve into any standard
hydrophilic or lipophilic solvent typically used for cellbased testing. Although tsotel can be decomposed by strong
acids or combusted to quantify amounts of chemically
‘pure’ mercury relative to other elements, the decomposition method destroys the complex substance considered
the ‘purified’ form by Sowa Rigpa. Accordingly, those using
reductionist methods that only quantify ‘pure’ elemental
mercury without analyzing its ‘pure’ compounded mercury
form by Sowa Rigpa would ask if the mercury in Sowa Rigpa
is a “Panacea or Problem” (Sallon et al. 2006: 405). However,
a follow-up clinical study by the same researchers finds: “…
mercury containing Tibetan Medicine does not have appreciable adverse effects and may exert a possible beneficial
effect on neurocognitive function” (Sallon et al. 2017:1, italics
added). Even though the study group taking high levels of
mercury in the form of tsotel showed improved functions of
attention, calculation, recall, and other measures compared
to low/no-mercury controls, the authors conclude: “Since
evidence of mercury as a toxic heavy metal, however, is
well known, further analysis of literature on mercury use
in other Asian traditional systems is highly suggested prior
to further studies” (ibid: 1).
While no harm is evident from tsotel use in this
well-designed human study, the researchers’ tone of
caution and distrust in the conclusion is not unfounded.
Considerable historical evidence exists on toxicity from
other mercury-containing compounds used as medicine. Elemental mercury, as gas, is one of the most toxic
elements known (Clarkson and Magos 2006), and toxic
mercury salts were a common treatment for syphilis
that Ehrlich’s detoxified arsenic magic-bullet ‘Salvarsan’
replaced. Since mercury is reactive with other elements,
many thousands of organic (carbon-substituted) and
inorganic (non-carbon) mercury compounds have been
synthesized and tested as patentable medicines, and many
have been found highly toxic in animal studies.
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However, mercury compounds vary widely in their toxicities (World Health Organization 2006). ‘Pure’ mercury
vapor, and small lipid-soluble organic mercuries, such
as methylmercury (HgCH3), can severely damage the
central nervous system, yet the toxicity of mercury sulfide
containing thimerosal used extensively as an antiseptic and
preservative during the late 1900s is still a topic of scientific debate (Baker 2008). Likewise, water soluble inorganic
mercury, such as mercury chloride (HgCl), can cause renal
and gastrointestinal toxicity (Li et al. 2018), yet cinnabar, an
insoluble mercuric sulfide (HgS) appears less toxic in most
animal studies (Clarkson and Magos 2006; Liu et al. 2008).
‘Pure’ HgS (red cinnabar) is poorly absorbed in the gut with
1000x less neurotoxicity than methylmercury and cinnabar
was not metabolized to the toxic methylmercury by human
gut bacteria in recent studies (Zhou et al. 2011). However,
renal toxicity may occur with long-term use (Liu et al. 2008),
and HgS administered to mice parents during conception/
development has been associated with neurotoxicological
effects in offspring (Huang et al. 2012). Interestingly, these
‘pure’ HgS results are consistent with Sowa Rigpa, which
also teaches that cinnabar is not to be used alone, in high
doses, nor without some ‘taming-purification’ processing
(Yeshi et al. 2018).
To prepare for cross-epistemology collaboration, questions
menjor specialists are called to answer are: what must the
pharmacologist understand about making and administering tsotel to investigate the potential complexed forms
of mercury in tsotel? What unique characteristics of tsotel
described by the tradition might inform a pharmacologist’s
hypothesis of chemical form related to action? Questions
pharmacologists are called to answer include: What are
the complexed forms of mercury in tsotel that are less toxic
than other forms of mercury? What is the mechanism, and,
what is the pharmacophore?
Several recent studies extend the standard 1-D elemental
analysis toward answering these questions. Using additional techniques, including 2-D powder X-ray diffraction
and others that do not chemically degrade the substance,
the authors determine tsotel is primarily mercuric sulfide
(HgS) nanocrystals, with excess sulfur and small amounts
of carbon and other elements. No signal for single element
mercury was found by the non-destructive analysis (Zhao
et al. 2013; Yan 2007; Li et al. 2016).
Previous 3D X-ray crystallography revealed that chemically, ‘pure’ HgS exists as ‘polymorph’ having at least two
relatively stable molecular crystal structure forms (Figure
5). The alpha (α) form, red cinnabar, can convert to the
beta (ß) black metacinnabar at high temperatures and
return to the red (α) form after cooling (Miguel et al. 2014).

Figure 5. HgS - Mercury (II) Sulfide Polymorphous Crystal Forms of
Cinnabar determined by 3D X-ray crystallography.
(Vladivostok, Marina. Cinnabar crystal structure. Wiki Commons,
2014: <https://commons.wikimedia.org/wiki/File:Cinnabar_crystal_structure.png>)
A) Characterized by X-ray diffraction, α-form ‘red cinnabar’ is the most
abundant source of mercury found on earth. Liquid HgS is precipitated by strong acids.
(Reno, Chris. Cinnabar09. Wiki Commons, 2007: <https://commons.wikimedia.org/wiki/File:Cinnabar09.jpg>; Mills, Ben. HgS Alpha Cinnabar.
Wiki Commons, 2010: <https://commons.wikimedia.org/wiki/File:HgSalpha-cinnabar-xtal-1999-looking-down-a-axis-CM-3D-balls.png>)
B) Characterized by X-ray diffraction, ß-form black cinnabar is a
rarer, higher energy form, generated by exposing the red form to high
temperatures or chemical synthesis. ‘Pure’ cubic HgS is unstable and
will revert to hexagonal upon cooling to room temperature. Can be
stabilized by organic substitution. Most abundant form identified in
tsotel samples.
(Lavinsky, Rob iRocks.com. Metacinnabar. WikiCommons, 2010:
<https://commons.wikimedia.org/wiki/File:Metacinnabar-233443.
jpg>; Mills, Ben. A zincblende unit cell. Wiki Commons, 2007: <https://
commons.wikimedia.org/wiki/File:Sphalerite-unit-cell-depth-fade-3Dballs.png>)

Figure 6. Scanning Electron Microscope (SEM) of tsotel powder
reveals clusters of ß-HgS nanoparticles ranging in size from >10
micron down to 10 nm.
(Li et al., 2016)

These two forms may provide clues toward defining the
pharmacophore for tsotel. A recent study comparing oral
administration of tsotel, ß-HgS, and HgCl in mice observed
kidney toxicity in HgCl-treated mice, but not in those
receiving tsotel or pure cubic ß-HgS. The authors suggest
only specific chemical species cause kidney toxicity in
mice and not all mercury forms (Li et al. 2018).
Interestingly, cubic HgS forms observed in tsotel powder
samples clustered into nanoparticles of varying size
from >10 micron down to 10 nm (Li et al. 2016) (Figure 6).
Nanoparticle engineering has become a growing area of
pharmacology study, and unlike small-molecule drugs that
enter cells by non-specific diffusion, nanoparticles only
enter specific cells through selective transport mechanisms (Oh and Park 2014). Consistent with how tsotel in
Sowa Rigpa functions similar to a menda, nanoparticles
are now being studied as medicine carriers. However, a

challenge to testing nanoparticles for activity/toxicity in
cells is often lack of aqueous solubility—like tsotel.
To address solvation, nanoresearch often employs various
carrier substances to suspend insoluble particles in aqueous
media (Taccola et al. 2011). Figure 6 illustrates dispersion,
micro, and nanomorphology of tsotel particles suspended
in a solution of acacia gum and water recorded by these
authors. Our observations of aqueous suspended tsotel as
clustered nanoparticle >10 micron down to 10 nm in diameter is consistent with that seen by the previous authors in
powder (Zhao et al. 2013; Yan 2007; Li et al. 2016). By sharing
epistemologies in a menjor-pharmacology collaboration, the
current authors successfully extended traditional preparation insights to modify standard analytical protocols.
To characterize this important complex compound, we
analyzed a pure water suspension with multiple non-destructive methods (Figure 7; Bai et al. in preparation).
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Figure 7. Transmission Electron
Microscope (TEM) images of
tsotel nanoparticles distributed
in aqueous suspension: A) Low
magnification shows random
dispersion of tsotel particles
(black spots) across grid cell B)
Medium magnification—spots
are actually clusters of smaller
clusters <100nm C) High
magnification reveals large
clusters are made of smaller
clusters of spherical particles <50
nm in diameter.
(Bai, Nettles, Tidwell, (c) 2017)

Conclusion: Toward a Sowa Rigpa Model of
Pharmaceutical Research
In the standard biochemical analysis approach assessing
medicinal activity, the pharmacological ‘purity’ concept
drives assessment methods. Individual, extracted
compounds are screened for properties and classified by
degree of toxicity, activity, and potency from a single
compound ‘purity’ perspective. Assuming that only a few
compounds in a substance are active is not a Sowa Rigpa
approach to purity and potency by which combinations of
single substances (and their vast multitude of molecular
compounds) interact synergistically to minimize toxicity
or facilitate potency. This requires the complexity of
numerous molecular compound interactions to provide
‘pure,’ or beneficial, medicinal products. However, such
reductionist methods are foundational to collect the data
needed for further biochemical research on synergy.
As seen in the second analytic approach, network pharmacology, systems biology, and metabolomics have vastly
improved methods for assessing potential complementary
mechanisms in multi-compound systems, such as in Sowa
Rigpa formulations. While analysis of constituent parts
can demonstrate specific activity mechanisms, more
analysis needs to focus on whole formula complexes as
done for Drébu Sum Tang. As the academic sector does
with synthetic pharmaceuticals, chemical library databases, derived from screening of Sowa Rigpa plants and
formulas, can potentially facilitate derivation of chemical
shape-based pharmacophores that can help explain active
chemical families described by taste, post-digestive taste,
potency, and quality profiles based in combinatorial
elemental dynamic properties. Such systems biology
approaches are inherently limited by assumptions made
during underlying data collection (Scheid 2016) and thus
require expert performance assessments. Sowa Rigpa
partners can serve this critical role by ensuring extraction
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solvents/methods resemble those traditionally used,20
suggest hypotheses for potential differences due to
extraction methods, advise functional evaluation targets,
and serve as gatekeepers to protect traditional knowledge.
The third collaboration type of composition-safety analysis
of complex compounds emphasizes the importance of
assessing structure to determine toxicity. This example
most clearly illustrates the distinctions in concepts of
‘purity’ between pharmacology and menjor. Tsotel is an
organo-metallic ornamented mercury sulfide nanoparticle
considered ‘pure’ on the Sowa Rigpa side because it is
made non-toxic, whereas the Euroamerican side assumes
‘toxicity’ based on the amount of chemically ‘pure’
mercury, not the actual form given to patients. A recent
study conducted by Liu and colleagues (2018) propagates
this misconception of mercury toxicity irrespective
of conjugated forms (such as mercury sulfide) into its
models of environmental pollution in Tibet from mercury,
which they attribute to the inclusion of tsotel in precious
pills consumed in Lhasa. The study highlights the purity
paradigm used by biomedically-trained chemists regarding
toxicity, as Liu and colleagues rely upon a destructive
method to evaluate amount of all elemental mercury (Liu
et al. 2018: 8839) and did not test for stable non-toxic forms
(Clarkson & Magos 2006; Liu et al. 2008; Zhou et al. 2011;
Morais et al. 2012; Li et al. 2016). Additionally, they greatly
overestimate the quantity and frequency of precious pill
consumption across Tibetan populations.
Given studies in animals showing effects in promoting
sleep, relaxation, reducing fever (Zeng et al. 2005; Jiang et
al. 2009), enhancing immunity, inhibiting expression of
caspase-3, reducing inflammation, and extending life in
fruit flies (Dorje and Lobu 2008; Chen et al. 2011; Zhu et al.
2013), and tsotel’s lack of toxicity in humans (Sallon 2017),
whole-formula follow-up studies in human cell lines to
determine mechanism are warranted. However, difficulty

of suspending tsotel particles in homogenous solutions
has inhibited cellular studies, as were done for Drébu Sum
Tang. Therefore, new methods for safety/potency testing
of such important substances in their Sowa Rigpa ‘purified’
nanoparticle forms are still needed.
In conclusion, we propose engaging the distinct epistemologies of different intellectual traditions by recognizing
key concepts such as the ‘purity’/‘potency’ paradigms
presented here. Such engagement, can generate new
understandings of ‘synergy-by-design’ for pharmacology
and a greater appreciation of unique chemical structures
and formulas for menjor.21 Accordingly, highly trained
Sowa Rigpa menjor partners in collaboration with interdisciplinary pharmacological teams can help design
experiments validating significant menjor developments by
encouraging pharmacology experts to explore more synergy-directed techniques and analysis beyond the single
lock/key model when studying Sowa Rigpa formulas.

Tawni L. Tidwell (PhD, Anthropology, Emory University,
2017; TMD (Kachupa-equivalent Menpa), Tibetan Medical
College, Qinghai University, 2015) is a Tibetan medical
physician and biological and cultural anthropologist. She was
a postdoctoral fellow with Project RATIMED (Reassembling
Tibetan Medicine) at the Institute of Social Anthropology,
Austrian Academy of Sciences, and with the FWF Potent
Substances Project at University of Vienna. Her work
focuses on pharmacological innovations in Tibetan medicine
and training practices in medicine compounding. Her
doctoral work detailed the entrainment process for learning
Tibetan medical diagnostics of Tibetan medical conceptions
of cancer and related metabolic disorders. Tidwell is
dedicated to facilitating dialogue and collaborations
between Tibetan medicine and Western science traditions,
and maintains a private clinical practice.
James H. Nettles (PhD, Molecular Pharmacology, Emory
University, 2005; Post-doctoral Fellow, Novartis Institute
for Biomedical Research, Cambridge, MA) specializes in
relating molecular structures to biological function. He is
past-director of drug-discovery modeling at the Laboratory
of Biochemical Pharmacology, Emory University School of
Medicine. His ongoing collaborations with academic and
industry partners combine biomedical informatics and
chemical structure modeling to explain drug activities and
acquired resistance/selectivity profiles for natural product
extracts as well as synthetic drug monotherapies used to
treat cancer and diverse viral diseases. He studies molecular
mechanisms of multi-component formulations, and is also
involved with clinical studies of wellness-oriented body/
mind therapy interventions such as massage, yoga, and
cognitive training.
The co-authors thank Geoffrey Samuels, Barbara Gerke, Jan van
der Valk, Stephan Kloos, Cassandra Quave, David Lynn, Michael
Iuvone, James Lyles, Yushi Bai, Jamyang Gyatso, Khenrab Gyamtso,
Jonathan Samuels and Tashi Dawa for valuable discussions. Parts
of this paper were presented in 2015 at the 1st Annual Tibetan
Medicine Specialty Committee WFCMS Conference in Xining,
Qinghai Province and 4th International Traditional and Modern
Medicine Conference in Xishuangbanna, Yunnan Province (PRC),
as well as in 2017 at the Mind-Body Health in Tibetan Medicine
Conference at Harvard Medical School in Cambridge (MA, USA).
The co-authors thank those who provided feedback at these
conferences, as well as the anonymous reviewers. TT was funded
by the ERC Award Number 336932 (Project RATIMED) at the
Austrian Academy of Sciences and the Austrian Science Fund
(FWF) Grant Number P30804-G24 at the University of Vienna.

HIMALAYA Volume 39, Number 1 | 143

Endnotes
1. Known as menpa, lhajé, or amchi (sman pa, lha rje, am chi).
2. Prominent commentaries for the discussion here
include: Kyempa Tsewang (2000 (15th cent.)); Zurkhar
Lodrö Gyalpo (1989 (16th cent.)); Deumar Tenzin Püntsok
(2009 (17th cent.)); Desi Sangyé Gyatso (1994, 2005 (17th
cent.)); Kongtrul Yönten Gyatso (2005 (19th cent.)); Troru
Tsenam (2000 (20th-21st cent.)).
3. Initiating from Tibet, Sowa Rigpa traditions spread
to and developed in Mongolia, Bhutan, Ladakh, Nepal,
Buryatia, Tuva, Kalmyk, and other Tibetan culturallyinfluenced regions. They share materia medica comprising
a wide breadth of minerals, gems, precious substances,
flora, and fauna with regional particularities for locally
procured specimens and similar sources for those distally
traded. Traditions regionalize to local ecologic, social,
cultural, philosophical, and epidemiologic contexts.
Disease theory and treatment approaches rely on systems
linking organs, fluids, bodily constituents, processes, and
activities described by specific functional characteristics
linking related activities modified by diet, behavior,
medicine, and therapeutic interventions. The Four Tantras
and its most prominent commentaries structure Sowa
Rigpa theory and praxis still used today of etiology,
diagnostics, and treatment applying these functional
characteristics of body physiology, material substances,
and therapeutic properties.
4. Sowa Rigpa menjor theory stems primarily from
Chapters 19-21 of “Explanatory Tantra,” and Chapters 3-12
of “Subsequent Tantra” on compounding distinctions in
the Four Tantras. Other important theoretical contributions
include: Chapters 1-3 and 5 of “Root Tantra;” treatment
sections of entire “Oral Instructions Tantra;” Chapters 1319 of “Subsequent Tantra,” and relevant external therapies
sections (Chapters 20-25).
5. Notable examples include anti-hypoxic activities
identified from Arenaria kansuensis (Cui et al. 2018), used
for altitude sickness in Sowa Rigpa; immunomodulatory
properties exhibited by five Sowa Rigpa plants emerging
as frontline treatment agents for cancer, infectious
disease and autoimmunity (Wangchuk et al. 2018); as well
as antimalarial activity identified against a multidrug
resistant Plasmodium falciparum strain from another Sowa
Rigpa plant (Wangchuk et al. 2013).
6. Another example is Sowa Rigpa-derived formulas tested
for the modulation of advanced glycation end products
and advanced oxidation protein products in bovine serum
albumin as a model protein (Grzebyk and Piwowar 2014).
7. Primarily from the work of Indian Buddhist logicians
Dignāga and Dharmakīrti after the 7th century CE.
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8. Even physiological pathways and activities in Sowa
Rigpa that, in their default mode, link body constituent,
organ, fluid, and energetic signaling dynamics to provide
systemic functions, relate to these elemental dynamics.
These psychophysiologic default systems are called the
three nyépa (nyes pa) or rlung (rlung), tripa (mkhris pa),
and béken (bad kan) responsible for functions of motility
and psychophysiologic signaling; metabolic heat, blood
production, and thermoregulation; and fluid-nutrient
cycling, filtration, joint lubrication, and solidity/cohesion,
respectively. Rlung exhibits properties of the elemental
wind dynamic, tripa the elemental fire dynamic, and
béken the elemental earth and water dynamics. The
Tibetan term nyépa refers to their activity as the primary
instigators of disease and imbalance in the body, like
a weakness that befalls the Achilles heel and results in
systemic debilitation. Although the standard phonetic
conversion (Germano and Tournadre 2010) for rlung is
‘lung’ (pronounced lōōng), we retain the Wylie spelling
‘rlung’ to distinguish the term and prevent confusion with
the organ lung.
9. Subcategories of the three nyépa physiological systems
named for their respective primary function.
10. For example: medicine composed of an earth dynamic
is heavy, stabilizing, dulling, smoothing, oiling, yet dry
in quality; often aromatic, and stiffening, bulkening,
cohering in functional activity. Due to interaction with
characteristic properties of nyépa pathways, earthdominant medicine pacifies rlung and increases béken.
11. Though narrower in scope than Euroamerican herb classes.
12. Known as the ‘Seven Essential Practices for
Cultivating Medicinal Quality’ (’sman la gces par ’os
pa’i yan lag bdun), comprising proper: (1) collection
location, (2) collection season and time of day, (3)
removal of harmful and toxic components, (4) drying
location according to warming and cooling principles,
(5) storage and suitable shelf life, (6) smoothing of
characteristics, and (7) compounding according to
specific desired properties of elemental dynamics,
tastes, post-digestive taste(s), potencies, qualities, and
various other characteristics (Yuthog Yönten Gönpo
2008: 696-700). For commentarial elaboration, see
Deumar Tenzin Püntsok (2009: 458-466).
13. We use ‘potentiate’ to gloss: “Drying and sorting
according to its own potency imbues immeasurable
qualities” (rang gi nus ldan yon tan dpag tu med) (Yuthog
Yönten Gönpo 2008: 697).
14. Sowa Rigpa traditions can vary in these practices (e.g.,
Boesi (2006); Dorje and Lobu (2008)).
15. For related discussions, see Yang Ga (2014) and
Tidwell (2017).

16. For example, taxol was one of the first compounds
isolated by government-funded natural product
extraction, and found to reduce abnormal growth of
cancerous tumors in mice during the 1960s. Later, in the
1990s, targeted screens focused on determining how (Wani
and Horowitz 2014).

Boesi, Alessandro. 2006. Plant Categories and Types in
Tibetan Materia Medica. Tibet Journal 30(4): 67–92.

17. Recent work by Klein and colleagues (2013) attempts
to minimize this limitation through pathway-focused
bioassays and transcriptome analysis.

Brown, Andrew W., Kathryn A. Kaiser, and David B. Allison.
2018. Issues with Data and Analyses: Errors, Underlying
Themes, and Potential Solutions. Proceedings of the National
Academy of Sciences 115(11): 2563–2570.

18. Funding mechanisms tend to drive this research
approach through supporting related infrastructure,
equipment, and analytical methods.
19. Jenny et al. (2005); Vennos et al. (2013); RadomskaLeśniewska et al. (2013); Grzebyk & Piwowar (2014).
20. Such as oil, boiled-water, ethanol, and so forth.
21. Bhutan healthcare policy (since 1967) placed
Sowa Rigpa practitioners alongside pharmacological
researchers to develop integrated scientific, quality
control, and safety/efficacy protocols (Wangchuk and
Tashi 2016). Several collaborations between top Tibetan
medical institutes in India and Tibet also used menjor/
pharmacology partnership approaches, such as Choedon
et al. (2014) and Schinazi and Dawa (2010). However,
understanding unique menjor aspects of synergy in
Sowa Rigpa has not been a direct focus of these past
collaborations. This article aims to contribute toward such
collaborative endeavors going forward.
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